Y-mAbs Therapeutics, Inc. (YMAB) Now Trades Above Golden Cross: Time to Buy?Zacks Investment Research • 09/01/25
Y-MABS THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Y-mAbs Therapeutics, Inc. - YMABGlobeNewsWire • 08/20/25
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q2 Loss, Tops Revenue EstimatesZacks Investment Research • 08/08/25
Shareholder Alert: The Ademi Firm Investigates Whether Y-mAbs Therapeutics Inc. is Obtaining a Fair Price for its Public ShareholdersBusiness Wire • 08/08/25
Y-mAbs Reports Second Quarter 2025 Financial Results and Recent Corporate DevelopmentsGlobeNewsWire • 08/08/25
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB)PRNewsWire • 08/07/25
Y-MABS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Y-mAbs Therapeutics, Inc. - YMABBusiness Wire • 08/07/25
Y-mAbs to Announce Second Quarter 2025 Financial and Operating Results on August 8, 2025GlobeNewsWire • 08/07/25
YmAbs Therapeutics (YMAB) Surges 103.3%: Is This an Indication of Further Gains?Zacks Investment Research • 08/06/25
Shareholder Alert: The Ademi Firm investigates whether Y-mAbs Therapeutics Inc. is obtaining a Fair Price for its Public ShareholdersPRNewsWire • 08/05/25
YMAB Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Y-mAbs Therapeutics, Inc. Is Fair to ShareholdersBusiness Wire • 08/05/25
YmAbs Therapeutics (YMAB) Upgraded to Buy: Here's What You Should KnowZacks Investment Research • 07/24/25
Y-mAbs Hosts Virtual Radiopharmaceutical R&D Update Highlighting Clinical Progress and Expanded PipelineGlobeNewsWire • 05/28/25
Y-mAbs Presents GD2-SADA PRIT Trial in Progress Poster at the Advances in Neuroblastoma Research MeetingGlobeNewsWire • 05/26/25
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q1 Loss, Tops Revenue EstimatesZacks Investment Research • 05/13/25
Y-mAbs Reports First Quarter 2025 Financial Results and Recent Corporate DevelopmentsGlobeNewsWire • 05/13/25
Y-mAbs Announces Update to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Neuroblastoma to Include Naxitamab-gqgk (DANYELZA®)GlobeNewsWire • 05/07/25
Y-mAbs to Announce First Quarter 2025 Financial and Operating Results on May 13, 2025GlobeNewsWire • 05/06/25
Earnings Preview: Y-mAbs Therapeutics, Inc. (YMAB) Q1 Earnings Expected to DeclineZacks Investment Research • 04/29/25
Y-mAbs Presents Translational Pharmacokinetics of CD38-SADA from Pretargeted RIT Platform at 2025 American Association for Cancer Research (AACR) Annual MeetingGlobeNewsWire • 04/27/25
Y-mAbs Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating CD38-SADA Pre-targeted Radioimmunotherapy in Relapsed/Refractory Non-Hodgkin LymphomaGlobeNewsWire • 04/25/25